Ardmore Shipping Corporation logo ASC - Ardmore Shipping Corporation

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 12
HOLD 5
SELL 0
STRONG
SELL 0
| PRICE TARGET: $19.00 DETAILS
HIGH: $19.00
LOW: $19.00
MEDIAN: $19.00
CONSENSUS: $19.00
UPSIDE: 23.38%

Stock News

Ardmore Shipping: The War Is The Wrong Reason To Own It - Buy

Ardmore Shipping: The War Is The Wrong Reason To Own It - Buy

Ardmore Shipping offers a compelling payout story, with Q2 spot MRs fixed at $52,100/day—nearly 5x cash breakeven—and a doubled dividend policy. ASC's Q2 earnings are largely locked in, supporting an estimated $0.83/share dividend and a projected $2.89/share full-year EPS at current run-rates. The stock is rated Buy with a $17 target, underpinned by a 12.4% yield, disciplined capital allocation, and a strong balance sheet with low leverage.

Jul 16, 2026 06:00 AM • seekingalpha.com
July Graham Value All-Stars (GVAS) Emit 10 Beaming Buys

July Graham Value All-Stars (GVAS) Emit 10 Beaming Buys

July's GVAS Dogs list highlights ten fair-priced, high-yield large-cap stocks, including IRSA Inversiones, Weibo, Verizon, and AT&T, as ideal buys. Analyst targets project average net gains of 40.39% for the top ten GVAS stocks by July 2027, with risk profiles generally below market volatility. The dividend dogcatcher strategy favors stocks whose $1K dividend income exceeds share price, with 36 of 54 GVAS stocks meeting this ideal condition.

Jul 11, 2026 02:01 AM • seekingalpha.com
Syntax Bio and Applied StemCell Announce Strategic Collaboration to Advance Stem Cell Innovation

Syntax Bio and Applied StemCell Announce Strategic Collaboration to Advance Stem Cell Innovation

CHICAGO & MILPITAS, Calif.--(BUSINESS WIRE)--Syntax Bio, a synthetic biology company programming the next generation of cell therapies, and Applied StemCell Corp. (ASC), a leader in induced pluripotent stem cell (iPSC) technology and genome engineering, today announced a strategic collaboration to help unlock the next generation of regenerative medicine. The collaboration will focus on evaluating ASC's iPSC and hypoimmune cell lines using Syntax Bio's proprietary Cellgorithm™ platform to advanc.

Jun 23, 2026 03:00 AM • businesswire.com
Ardmore Shipping Exercises Newbuilding Options

Ardmore Shipping Exercises Newbuilding Options

HAMILTON, Bermuda, June 16, 2026 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore" or the "Company") today announced it has exercised the options for two additional 40,500 dwt Handysize product/chemical tankers to be built at Wuhu Shipyard, thereby expanding the original order to four vessels in total on the same terms. The deliveries of these four vessels are scheduled from late 2028 and onwards.

Jun 16, 2026 12:35 PM • prnewswire.com
13 Lucky Dogs: June Graham Value All-Stars (GVAS)

13 Lucky Dogs: June Graham Value All-Stars (GVAS)

The June GVAS portfolio highlights 13 'safer,' fair-priced large-cap value stocks with strong dividend yields and positive free cash flow margins. Top ten GVAS stocks are forecasted to deliver average net gains of 39.68% by June 2027, with yields ranging from 7.9% to 16.46%. Energy and financial sectors dominate the highest-yielding, lowest-priced GVAS, with Okeanis Eco Tankers and IRSA Inversiones offering standout upside potential.

Jun 04, 2026 03:49 AM • seekingalpha.com
Ardmore Shipping Corporation Announces Financial Results For The Three Months Ended March 31, 2026

Ardmore Shipping Corporation Announces Financial Results For The Three Months Ended March 31, 2026

HAMILTON, Bermuda, May 7, 2026 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore", the "Company" or "we") today announced results for the three months ended March 31, 2026. Highlights and Recent Activity Reported Adjusted earnings and net income attributable to common stockholders of $23.6 million for the three months ended March 31, 2026, or $0.58 Adjusted earnings per basic and diluted share, compared to Adjusted earnings and net income attributable to common stockholders of $5.6 million, or $0.14 Adjusted earnings per basic and diluted share for the three months ended March 31, 2025.

May 07, 2026 04:00 AM • prnewswire.com
Ardmore Shipping Provides Update on Fleet Investment, Dividend Policy, and Vessel Sale

Ardmore Shipping Provides Update on Fleet Investment, Dividend Policy, and Vessel Sale

Signed contracts for the construction of two option two 40,500 dwt IMO2 product/chemical tankers Doubling dividend payout ratio to two-thirds of adjusted earnings, effective 1Q 2026 Agreed sale of one 2014-built MR tanker for $35.5 million with June delivery MR Spot TCEs of $33,700 per day for 1Q 2026 and fixed $50,000 per day in 2Q 2026 to-date HAMILTON, Bermuda, April 29, 2026 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore" or the "Company") today provided the following update on capital allocation, vessel sale, and latest TCE guidance. Fleet Investment The Company signed contracts for the construction of two highly-efficient and versatile 40,500 dwt Handysize product/chemical tankers at Wuhu Shipyard, at a price of $44.9 million per vessel, inclusive of approximately $3 million for full IMO2 specification and MarineLine tank coatings.

Apr 29, 2026 04:22 AM • prnewswire.com
Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development

Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development

-Fixed - dose combination of ASC30 and ASC39 (ASC30_39 FDC) tablets, dosed orally in dogs, demonstrated comparable pharmacokinetics to those observed in their respective monotherapies in a head-to-head study . The fixed dose combination had excellent oral bioavailability, drug exposure and a half -life of up to 12 hours.

Apr 07, 2026 03:00 AM • prnewswire.com
ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update

ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update

ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion. Inflammasome ASC Inhibitor IC 100 is a next generation drug designed for unparalleled control of disease-causing inflammation by (1) inhibiting multiple inflammasomes activated in numerous diseases, not just NLRP3, and (2) attenuating spread and perpetuation of inflammation by uniquely inhibiting ASC specks.

Mar 31, 2026 01:05 PM • globenewswire.com

Price Targets